



PharmaMar to Hold Fourth Quarter Financial Results Conference Call and Webcast on Friday, February 24th, 2017

Madrid, February 22, 2017 – PharmaMar (MSE:PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, today announced that it will release Fourth Quarter and Year-End 2017 financial results on Thursday, February 23, 2017. Further, PharmaMar management will host an investment-community conference call at 8:00 a.m. ET on Friday February 24, 2017 to discuss the financial results and to provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing 877-407-3102 for U.S. and Canadian callers or 201-493-6790 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the [Events Calendar](#) page of the company's website at www.pharmamar.com and clicking on the webcast link.

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the [Events Calendar](#) page of the company's website at www.pharmamar.com.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127

Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215

Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

###

